| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
7-Hydroxyquetiapine targets dopamine D2 receptors and serotonin 5-HT2A receptors, similar to its parent drug quetiapine. As a metabolite, it exhibits mixed dopamine and serotonin receptor antagonistic properties, which are characteristic of atypical antipsychotics. It has lower affinity for histamine H1 and adrenergic alpha1 receptors compared to quetiapine. The metabolite may also interact with 5-HT1A and 5-HT7 receptors.
|
|---|---|
| ln Vitro |
In vitro, 7-Hydroxyquetiapine shows receptor binding profiles similar to quetiapine but with distinct selectivity. It exhibits high affinity for serotonin 5-HT2A receptors (Ki ∼ 11 nM) and moderate affinity for dopamine D2 receptors (Ki ∼ 260 nM). The metabolite shows reduced affinity for histamine H1 (Ki ∼ 310 nM) and alpha1-adrenergic receptors compared to the parent drug, potentially resulting in a more favorable side effect profile with less sedation and orthostatic hypotension.
|
| ln Vivo |
In vivo, 7-Hydroxyquetiapine is an active metabolite that reaches concentrations similar to quetiapine in plasma following therapeutic dosing. It contributes significantly to the antipsychotic efficacy of quetiapine, especially for negative symptoms of schizophrenia. In animal models, the metabolite shows dose-dependent occupancy of D2 and 5-HT2A receptors in the brain, correlating with antipsychotic-like effects in behavioral assays.
|
| Enzyme Assay |
7-Hydroxyquetiapine can be tested in non-cellular receptor binding assays. The compound is dissolved in DMSO or ethanol to prepare a stock solution, then diluted into assay buffer (e.g., 50 mM Tris-HCl, pH 7.4). Radioligand binding assays are performed using membrane preparations from cells expressing human dopamine D2 or serotonin 5-HT2A receptors. Membranes are incubated with radioligands (e.g., [3H]spiperone for D2, [3H]ketanserin for 5-HT2A) and varying concentrations of 7-Hydroxyquetiapine. After incubation, bound and free radioligands are separated by filtration, and radioactivity is counted to calculate IC50 and Ki values.
|
| Cell Assay |
For in vitro cellular assays, cells expressing dopamine D2 receptors or serotonin 5-HT2A receptors (e.g., CHO or HEK293 stable transfectants) are cultured in DMEM with 10% FBS. Cells are seeded in 96-well plates and treated with 7-Hydroxyquetiapine at various concentrations (e.g., 0.1 nM-100 uM). For functional assays (e.g., calcium flux, cAMP inhibition), cells are loaded with calcium-sensitive dyes (e.g., Fluo-4 AM) or pre-incubated with forskolin. Receptor activation is measured using fluorescence or chemiluminescence plate readers, and EC50/IC50 values are calculated.
|
| Animal Protocol |
For in vivo animal studies, 7-Hydroxyquetiapine can be administered to rodents via intraperitoneal injection (e.g., 1-10 mg/kg) or oral gavage. Plasma and brain tissue are collected at various time points (e.g., 0, 30, 60, 120, 240 minutes) after administration. Brain and plasma concentrations are analyzed by LC-MS/MS. Behavioral studies such as conditioned avoidance response or PCP-induced hyperlocomotion can be performed to assess antipsychotic-like effects in relation to brain exposure levels.
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
7-Hydroxyquetipine is a known human metabolite of quetiapine. 7-Hydroxyquetiapine has a plasma half-life of approximately 6-8 hours in humans, similar to quetiapine. In healthy subjects, the metabolite is eliminated primarily via renal excretion, with approximately 20-30% excreted unchanged in urine. The area under the plasma concentration-time curve (AUC) of 7-Hydroxyquetiapine is approximately 30-50% of quetiapine's AUC. The compound crosses the blood-brain barrier, achieving brain concentrations similar to those in plasma. |
| Toxicity/Toxicokinetics |
7-Hydroxyquetiapine shares similar toxicity considerations with quetiapine. Common side effects at therapeutic doses include somnolence, dizziness, dry mouth, and weight gain. The metabolite has reduced affinity for histamine H1 receptors compared to quetiapine, potentially resulting in less sedation. Overdose may cause drowsiness, tachycardia, and hypotension. Standard laboratory precautions for handling antipsychotic compounds (gloves, safety glasses) are recommended.
|
| References | |
| Additional Infomation |
7-Hydroxyquetiapine is not a marketed drug but the major active metabolite of quetiapine. Quetiapine (Seroquel®) is FDA-approved for the treatment of schizophrenia, bipolar disorder (manic and depressive episodes), and major depressive disorder as adjunctive therapy. 7-Hydroxyquetiapine is used as a certified reference standard for LC-MS/MS methods in clinical toxicology and therapeutic drug monitoring. It is valuable for distinguishing quetiapine use from other antipsychotics in forensic and compliance testing.
|
| Molecular Formula |
C21H25N3O3S
|
|---|---|
| Molecular Weight |
399.51
|
| Exact Mass |
399.162
|
| CAS # |
139079-39-3
|
| Related CAS # |
7-Hydroxy Quetiapine-d8;1185098-57-0;7-Hydroxyquetiapine-d4 hemifumarate
|
| PubChem CID |
132203
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.33 g/cm3
|
| Boiling Point |
612.4ºC at 760 mmHg
|
| Melting Point |
56-60ºC
|
| Flash Point |
324.2ºC
|
| Vapour Pressure |
7.5E-16mmHg at 25°C
|
| Index of Refraction |
1.666
|
| LogP |
1.873
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
28
|
| Complexity |
527
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C2C(=C1)C(=NC3=C(C=C(C=C3)O)S2)N4CCN(CC4)CCOCCO
|
| InChi Key |
VEGVCHRFYPFJFO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H25N3O3S/c25-12-14-27-13-11-23-7-9-24(10-8-23)21-17-3-1-2-4-19(17)28-20-15-16(26)5-6-18(20)22-21/h1-6,15,25-26H,7-14H2
|
| Chemical Name |
6-[4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl]benzo[b][1,4]benzothiazepin-2-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5031 mL | 12.5153 mL | 25.0307 mL | |
| 5 mM | 0.5006 mL | 2.5031 mL | 5.0061 mL | |
| 10 mM | 0.2503 mL | 1.2515 mL | 2.5031 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
